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Background: Although T cells, especially CD8+, have been implicated in chronic obstructive pulmonary disease
(COPD) pathogenesis, their role during acute exacerbations (AE-COPD) is uncertain.
Methods: We recruited subjects with COPD and a history of previous AE-COPD and studied them quarterly to
collect blood and spontaneously expectorated sputum while stable. During exacerbations (defined by a change in
symptoms plus physician diagnosis and altered medications), we collected blood and sputum before administering
antibiotics or steroids. We used flow cytometry to identify leukocytes in peripheral blood, plus Luminex® analysis or
ELISA to determine levels of inflammatory biomarkers in serum and sputum supernatants.
Results: Of 33 enrolled subjects, 13 participated in multiple stable visits and had ≥1 AE-COPD visit, yielding 18
events with paired data. Flow cytometric analyses of peripheral blood demonstrated decreased CD4+ and CD8+ T
cells during AE-COPD (both absolute and as a percentage of all leukocytes) and significantly increased granulocytes,
all of which correlated significantly with serum C-reactive protein (CRP) concentrations. No change was observed in
other leukocyte populations during AE-COPD, although the percentage of BDCA-1+ dendritic cells expressing the
activation markers CD40 and CD86 increased. During AE-COPD, sICAM-1, sVCAM-1, IL-10, IL-15 and GDF-15
increased in serum, while in sputum supernatants, CRP and TIMP-2 increased and TIMP-1 decreased.
Conclusions: The decrease in CD4+ and CD8+ T cells (but not other lymphocyte subsets) in peripheral blood
during AE-COPD may indicate T cell extravasation into inflammatory sites or organized lymphoid tissues. GDF-15, a
sensitive marker of cardiopulmonary stress that in other settings independently predicts reduced long-term survival,
is acutely increased in AE-COPD. These results extend the concept that AE-COPD are systemic inflammatory events
to which adaptive immune mechanisms contribute.
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Chronic obstructive pulmonary disease (COPD) is a pro-
gressive, debilitating and highly prevalent condition that is
believed to result from an abnormal response to inhaled
oxidants and which is characterized by lung destruction,
airways remodeling, and mucus hypersecretion. COPD is
punctuated by episodic worsening in respiratory function
and symptoms, termed acute exacerbations of COPD
(AE-COPD). These events are associated with accelerated
lung function decline, reduced quality of life [1, 2], plus in-
creased mortality, which is appreciable for events requir-
ing hospitalization and which persists for at least five
years [3, 4]. AE-COPD also drive the majority of the eco-
nomic burden of this common disease [5]. Preventing
these expensive and potentially lethal events should be a
major public health goal.
Despite this great impact of AE-COPD, understanding
of the responsible pathogenic mechanisms remains in-
complete. There is consensus that a plurality of AE-COPD
are associated with isolation of respiratory microbes, with
some contribution from environmental triggers [6–8], and
some events lacking evidence of inflammation, currently
of incompletely understood etiology [9]. However, the
acute beneficial role of systemic steroid therapy suggests
that overly-exuberant inflammation, rather than simply
presence of microbes, might determine symptomatol-
ogy in most AE-COPD. Hence, continued investiga-
tion of inflammatory mechanisms during AE-COPD
remains important.
We have hypothesized that AE-COPD would be associ-
ated with systemic evidence of inappropriate immune acti-
vation, especially of the adaptive immune system [10]. Lung
T cells, especially CD8+ T cells, have been implicated in
COPD pathogenesis [11–13], but data on their role in AE-
COPD are limited. During AE-COPD, numbers of lympho-
cytes increase in both sputum and airway biopsies [14–16]
and a CD8+ type-2-mediated immune reaction has been
identified in sputum [17]. However, in the peripheral blood,
a practical sample for monitoring systemic responses, there
are few data during AE-COPD on the activation status and
phenotype of immune cells or on their correlation with cir-
culating biomarkers. The lack of universally-accepted
animal models of AE-COPD necessitates use of human
samples to address this question.
To that end, we designed a prospective cohort study
to investigate subjects during the stable state and at on-
set of AE-COPD. Peripheral blood was used for both
immunophenotyping of various leukocytes populations
and to analyze 41 analytes in serum. Sputum superna-
tants were used to analyze 36 analytes. Our results pro-
vide novel data supporting AE-COPD as systemic
inflammatory events to which T cells contribute, and
which even when not requiring hospitalization, are as-
sociated with pulmonary vascular stress.Materials & methods
Study design
This observational longitudinal cohort study aimed to col-
lect biomarkers of AE-COPD, for paired, within-subject
comparison with samples collected at enrollment during
clinical stability. Accordingly, we recruited participants at
high risk of repeated AE-COPD who agreed to return to
the study sites during suspected exacerbations. Individual
subjects were followed for up to 3 years.
Ethics, consent and permissions
Subjects were recruited both from Pulmonary and General
Medicine clinics at VA Ann Arbor Healthcare System
(VAAAHS) and the University of Michigan Health System
(UMHS) and by use of additional media (flyers, UMHS
website for clinical research volunteers). Studies and con-
sent procedures were performed in accordance with the
Declaration of Helsinki and were approved by each site’s
Institutional Review Board. Written consent to participate
was obtained before any study procedures. All participants
understood the purpose of the study and consented to
publication of individual data. The study period was from
December 2006 until March 2010.
Subject population & participation
Subjects were enrolled while clinically stable ≥6 weeks
post AE-COPD or other use of antibiotics. Inclusion cri-
teria were a diagnosis of COPD by GOLD guidelines [18];
a post-bronchodilator forced expiratory volume in one
second (FEV1) of ≤ 70 % predicted; cigarette smoking
exposure ≥ 20 pack years; 40 years ≤ age ≤ 80 years; daily
productive cough ≥3 months annually for two consecutive
years; and at least one AE-COPD requiring medical atten-
tion and a medication change (addition of oral steroids,
antibiotics or both) annually for the previous three years.
Exclusion criteria included unstable heart disease; ill-
nesses anticipated to result in death within two years; pred-
nisone > 20 mg per day; asthma, cystic fibrosis, clinically
significant bronchiectasis, lung cancer, or other inflamma-
tory or fibrotic lung diseases.
Participants underwent spirometry, prospectively-
collected questionnaires, clinical evaluation by a pul-
monologist, posterior-anterior and lateral chest ra-
diographs and collection of peripheral blood and
spontaneously expectorated sputum at enrollment and
during unscheduled visits when they sought medical at-
tention for presumptive AE-COPD. During scheduled
follow-up visits when participants were clinically stable,
study coordinators performed identical data collection
and evaluation (omitting radiographs).
AE-COPD was defined as a change above baseline in re-
spiratory symptoms (increased dyspnea, cough, and sputum
volume or purulence) plus addition by a study physician of
antibiotics, oral steroids or both, based on review of history,
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pneumonia. A diagnosis of AE-COPD was made prior to
collection of samples (so study physicians had no know-
ledge of biomarker results, including serum CRP) and of
the Breathlessness, Cough, and Sputum Scale question-
naire. Only if the unscheduled visit was determined
clinically to be an AE-COPD meriting treatment using
oral steroids, antibiotics or both, were peripheral
blood and spontaneously expectorated sputum speci-
mens collected, which occurred before initiating any
new medications.
Sample collection & processing
Peripheral blood was collected into two Vacutainer blood
collection tubes (Becton Dickinson, Franklin Lakes, NJ).
One containing heparin was used for whole blood flow cy-
tometric analyses; the other without additives was allowed
to clot for 30 min at room temperature before centrifuga-
tion and then serum was collected into cryovials and
stored at −80 °C until analysis.
Spontaneously expectorated sputum was immediately
transferred to the laboratory, on ice, for processing.
Dense, non-liquid portions of sputum were selected and
weighed. Sputolysin® (EMD Millipore, Billerica, MA) was
prepared by dissolving a 1 mL vial in 9 mL distilled
water. The prepared Sputolysin was added at 2x the
weight of the sputum and incubated in a 37 °C water-
bath with vortexing every 5 min until the sample became
viscous. An equal volume of PBS was added and the
mixture was filtered through a 48 μm nylon gauze mesh
filter, centrifuged and the supernatant was stored at
−80 °C until analysis.
Flow cytometry
Whole blood was dispersed into tubes (100 μL each)
containing antibodies and incubated for 25 min, pro-
tected from light, with shaking. BD FACS™ Lysing Solu-
tion (Becton Dickinson) was used to lyse erythrocytes
according to manufacturer’s instructions. We used
monoclonal antibodies from a variety of vendors as indi-
cated in Additional file 1: Supplemental Materials &
Methods. We assessed viability in all experiments using
a Live/Dead Fixable Near-IR Dead Cell Stain Kit for
633 nm excitation (Invitrogen, Carlsbad, CA). Immedi-
ately after staining, cells were fixed by addition of stain-
ing buffer containing 2 % paraformaldehyde; tubes were
then stored at 4 °C in a rack wrapped in aluminum foil
until analyzed.
Staining was analyzed on a LSR II flow cytometer
(BD Bioscience, San Jose, CA), equipped with four la-
sers as described in detail [19]. Data were collected
using FACSDiva software (BD Biosciences) with auto-
matic compensation and were analyzed using FlowJo
software (Tree Star, Ashland, OR). We collected at least10,000 viable CD45+ events per sample in each experi-
ment. Details of our gating strategy are provided in
Additional file 1: Supplemental Materials & Methods,
and have recently been published together with repre-
sentative raw data [20].
Serum & sputum protein measurements
Serum and sputum samples were stored at −80 °C until
all could be analyzed simultaneously. We used two
methodologies to analyze protein concentrations. The
majority of analytes were measured using a Luminex
200 system® (Luminex Corporation, Austin, TX), accord-
ing to the manufacturer’s instructions. We used multi-
plex bead sets from a variety of vendors as indicated in
Additional file 1: Supplemental Materials & Methods.
For four analytes (GDF-15, IL-18, IL-23p19 and IFN-β),
multiplex beads were not available; instead, ELISAs were
used according to manufacturers’ instructions.
Statistical analyses
We used GraphPad Prism 6.0 (GraphPad Software, Inc.,
La Jolla, CA) on a Macintosh Quad-Core Intel Xeon
computer running OS 10.8.3 (Apple; Cupertino, CA).
We used Wilcoxon matched-pairs signed rank test to
look for differences between stable and exacerbation
visits. A two-tailed p value of < 0.05 was considered to
indicate significance. Spearman nonparametric correl-
ation coefficient was used.
Results
Patient enrollment and completion
We enrolled 33 COPD subjects; six completed only the
baseline visit and were excluded. Another 14 subjects
completed multiple visits in the stable state; however, 13
did not complete an AE-COPD visit, despite an interval
self-reported AE-COPD, and were excluded. A single
subject did not have any AE-COPD. The remaining 13
subjects participated in multiple stable visits and had ≥1
AE-COPD visit, yielding 18 total events with paired
stable and AE-COPD data. Age, sex, smoking history,
spirometry, number of AE-COPD, and inhaled cortico-
steroid (ICS) use for each of the 13 subjects are shown
(Table 1). All events were treated successfully in the out-
patient setting.
Among the 18 captured AE-COPD events, 14 oc-
curred 2–13 months after the preceding stable visit
(5.3 ± 3.2 months, mean ± SD). However, in the other
four, the AE-COPD occurred within one week after a
scheduled stable visit. Given the possibility that data
were not collected during a period of true stability, in
these analyses we instead used paired data from a sub-
sequent scheduled stable visit 2–5 months after the
AE-COPD.
Table 1 Summary of demographics, spirometry, smoking history and medications1
Age (years) Sex FEV1 (% predicted) Smoking (pack-years) Smoking status # of AE-COPD during enrollment ICS use (Y/N) Home oxygen (Y/N)
67 M 52 108 Active 1 Y N
74 F 51 50 Former2 3 Y N
73 M 50 115 Former 1 Y Y
59 M 47 18 Former 1 Y Y
72 M 36 39 Former 2 Y Y
66 F 33 104 Active 1 Y Y
72 M 31 120 Active 1 Y Y
66 M 29 40 Active 1 N N
77 M 28 50 Former 1 Y N
58 M 26 25 Former 1 Y N
65 M 21 40 Former 1 Y Y
67 M 20 84 Active 1 Y Y
69 M 14 98 Former 3 Y Y
68.1 ± 5.61 11/2 33.7 ± 12.7 68.5 ± 36.9 8/5 1.38 ± 0.77 12/1 8/5
1Data are presented as average ± SD, except for sex ratios (M/F), smoking status (Former/ Active) and ICS use (Yes/No); M, male; F, female; ICS, inhaled
corticosteroids; 2former smokers were defined as having quit for more than six months
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elevated CRP levels
All decisions to treat and hence to collect data at an AE-
COPD visit were made by clinicians blinded to data from
study questionnaires or biomarkers. However, as an inde-
pendent confirmation that subjects were experiencing an
actual AE-COPD, we retrospectively evaluated the severity
of respiratory symptoms using the Breathlessness, Cough,
and Sputum Scale (BCSS) [21]. The BCSS is based on a
three-item questionnaire rating breathlessness, cough and
sputum on a scale of 0 (no symptoms) to 4 (severe symp-
toms), which are summed. BCSS total score significantly
increased during AE-COPD (Fig. 1a), from a median of
3.5 during stable visits to 8.0 during AE-COPD.
A study published shortly before the launch of ours,
which assessed the ability of 36 different biomarkers to con-
firm the presence of AE-COPD and to predict their sever-
ity, found CRP to be the most selective analyte [22]. Serum
CRP levels in our subjects, which were measured by the
clinical laboratories, were also significantly increased during
AE-COPD (Fig. 1b) (stable, 0.58 ± 0.40 mg/dL vs. AE-
COPD, 6.4 ± 7.5 mg/dL; mean ± SD). In our study, BCSS
correlated with CRP levels (r = 0.43, p = 0.011). Collectively,
these findings provide additional evidence that these events
were valid AE-COPD.
Peripheral blood CD4+ and CD8+ T cells decreased
during AE-COPD
CD4+ T cells and CD8+ T cells significantly decreased in
the blood during AE-COPD, relative to the paired stable
visit (Fig. 2a-d). This change occurred both as a percent ofall CD45+ cells (CD4+ T cells: stable, 17.4 ± 1.7 % of
CD45+ leukocytes vs. during AE-COPD, 10.0 ± 4.2 %;
mean ± SEM; p = 0.002) (CD8+ T cells: stable, 10.4 ±
2.2 % vs. AE-COPD, 5.9 ± 1.0 %; p = 0.02) and in
absolute numbers. By Spearman correlation analyses,
CD4+ and CD8+ T cells correlated significantly and
inversely with serum CRP, both relatively (percentage
CD4+ T cells: r = −0.74, p < 0.0001; percentage CD8+
T cells: r = −0.46, p = 0.005) and as absolute cell num-
bers (CD4+ T cells: r = −0.60, p = 0.0001; CD8+ T cells:
r = −0.41, p = 0.013).
We did not see changes during AE-COPD in the distri-
bution in peripheral blood of B cells, NK cells or any of the
three types of DCs, in either relative or absolute terms.
However, CD15+ granulocytes increased significantly
(Fig. 2e-f), both as a percent of CD45+ cells (stable, 54.5 ±
4.3 % of CD45+ cells vs. AE-COPD, 68.9 ± 3.3 %) and in ab-
solute numbers. CD15+ cells correlated directly with serum
CRP (percentage CD15+ cells, r = 0.59, p = 0.0003; absolute
CD15+ cells, r = 0.49, p = 0.003).
Because the flow cytometric staining used in this
study had not been designed to distinguish neutro-
phils from eosinophils, we retrospectively examined
data from the differential cell counts performed by
the clinical laboratories. There were no significant
changes in eosinophils during AE-COPD in our subjects
(stable, 2.59 ± 2.0 % vs. AE-COPD, 1.41 ± 0.83 %; mean ±
SEM, n = 15 events; p = 0.170). By contrast, results of the
clinical differential counts confirmed that the change in
granulocytes we observed was due to an increase in neutro-
phils (stable, 70.71 ± 5.37 % vs. AE-COPD, 79.04 ± 8.29 %;
p < 0.0001
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Fig. 1 AE-COPD confirmed by increases in BCSS total score and
serum CRP levels. AE-COPD events were identified by physician
diagnosis (after exclusion of pneumonia by chest radiograph)
plus the clinical decision to prescribe oral steroids or antibiotics.
Although these decisions were blinded to biomarker results,
the diagnosis of AE-COPD was retrospectively confirmed by
highly significant increases in (a) BCSS total scores and (b) serum
CRP levels. Open circles represent individual subjects; mean ±
SEM of the grouped data are shown by the single red circles. The
Wilcoxon matched-pairs signed rank test was used to determine
significant differences between visits
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(stable, 266.6 ± 47.2 × 103/μL vs. AE-COPD, 258.4 ± 54.4 ×
103/μL; p = 0.33).
Data from representative individuals demonstrated a
recurring pattern, in which AE-COPD were marked by
decreased percentages of both CD4+ and CD8+ T cells
in peripheral blood, followed by a rebound in those cell
types at the next stable visit (Fig. 3). Interestingly, in
some subjects who had a scheduled visit shortly before a
clinically-defined exacerbation (Fig. 3a, b), the decline in
cell frequency could actually be observed shortly before
the AE-COPD. This finding suggests that immune acti-
vation might precede symptoms, but a larger study will
be needed to test that possibility. In contrast, the solesubject with no reported AE-COPD events did not dis-
play a change in T cell frequency (Fig. 3e).
Activation markers CD40 and CD86 are increased on
BDCA-1 DCs during AE-COPD
We also analyzed the surface expression of receptors
specific to the various leukocyte populations. On both
CD4+ and CD8+ T cells, we analyzed CD69, CD25,
CD27, CD62L and IL-18R, which collectively contribute
to defining T cell activation history. There was no differ-
ence in the percentage of T cells expressing these recep-
tors between stable and AE-COPD visits, nor were there
any significant changes in B cells or NK cells (data not
shown). On the three DC population, we analyzed the
activation and maturation markers CD40, CD80, CD83
and CD86. Despite an absence of change in the numbers
or frequency of DCs, we found that the percentage of
mDC1 that expressed CD40 and CD86 increased signifi-
cantly during AE-COPD (Fig. 4). By contrast, expression
of CD80 and CD83 did not change on mDC1, nor were
there any significant changes in receptor expression on
mDC2 or pDC (not shown).
Increased production of specific analytes in the serum
during AE-COPD
We analyzed serum for 41 different analytes using a
combination of Luminex® and ELISA assays (Table 2). In
addition to CRP, considered above, five analytes in-
creased significantly during AE-COPD: soluble intracel-
lular adhesion molecule (sICAM)-1, soluble vascular cell
adhesion molecule (sVCAM)-1, IL-10, IL-15, and growth
and differentiation factor 15 (GDF-15) (Fig. 5a-e). Serum
IL-15 measurements during stable visits were at or near
the limit of detection, however IL-15 levels were signifi-
cantly increased in all but one of the AE-COPD events.
Interestingly, CCL11 showed a trend to decrease during
AE-COPD (Fig. 5f ), which did not attain statistical
significance (stable, 79.7 ± 41.1 pg/mL vs. AE-COPD,
67.8 ± 56.7 pg/mL; mean ± SD; p = 0.052).
AE-COPD leads to decreased TIMP-1 and increased TIMP-2
production in the sputum
We also analyzed sputum supernatants for 36 different
analytes using a combination of Luminex® and ELISA as-
says (Table 2). Significant increases during AE-COPD were
found for CRP and tissue inhibitor of metalloproteinase
(TIMP)-2, while TIMP-1 levels in sputum decreased dur-
ing AE-COPD (Fig. 6). IL-6 and IL-8 levels in sputum also
increased slightly during AE-COPD, but did not reach stat-
istical significance (IL-6: stable, 117.1 ± 108.2 pg/mL vs.
during AE-COPD, 225.9 ± 193.5 pg/mL; IL-8: stable,
3.7×103 ± 2.6×103 ng/mL vs. AE-COPD, 5.5×103 ± 4.3×103
ng/mL; mean ± SD, p = 0.16 for both analytes).
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Fig. 2 Peripheral blood CD4+ and CD8+ T cells decreased during AE-COPD while CD15+ granulocytes increased. Peripheral blood was collected
during stable visits and during AE-COPD, prior to medication (n = 18 paired samples). Cells were stained and analyzed by flow cytometry. Results
are shown for the individual cell type as a percentage of all CD45+ leukocytes (a, c, e) and as absolute cell numbers per μL (b, d, f). A, B. CD4+ T
cells. C, D. CD8+ T cells. E, F. CD15+ cells; note difference in scale of panels E & F. Open circles represent individual subjects; mean ± SEM of the
grouped data are shown by the single red circles. The Wilcoxon matched-pairs signed rank test was used to determine significant differences
between visits
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This observational study of paired samples from COPD
subjects in the stable and exacerbated states demonstrates
that CD4+ T cells and CD8+ T cells decreased in peripheral
blood during AE-COPD. Decreases occurred both in abso-
lute numbers and as a percentage of all leukocytes, and
were noted repeatedly in those with multiple AE-COPD.
We found no changes during AE-COPD in numbers or
percentages of B cells, NK cells or DCs in peripheral blood,
although numbers of neutrophils increased, as did expres-
sion of CD40 and CD86 by BDCA-1+ DC, compatible with
activation. We also demonstrate significant increases during
AE-COPD in serum levels of GDF-15, a sensitive marker of
cardiopulmonary stress that in other settings predicts re-
duced long-term survival, and of IL-10, IL-15, sICAM and
sVCAM. These results extend the concept that AE-COPD
are systemic inflammatory events to which adaptive im-
mune mechanisms contribute.Determining whether lymphocyte recruitment should
be targeted to improve AE-COPD clinical outcomes re-
quires defining whether lung inflammation depends on
that recruitment, or conversely can be mediated by the
newly recognized and sizeable populations of lung resi-
dent lymphocytes [23, 24]. As assessed by bronchoalveo-
lar lavage, CD4+ T cells are reduced in the lungs of
active smokers without airflow obstruction [25] and in
active smokers regardless of airflow obstruction [26],
whereas bronchial biopsies showed increased intrae-
pithelial CD4+ T cells in COPD patients, relative to
smokers and never-smokers [27]. In terms of function,
we recently showed that lung resident CD4+ T cells in
many subjects with stable advanced COPD have very re-
duced ability to produce inflammatory cytokines, either
spontaneously or on polyclonal stimulation, relative to
subjects without COPD [28]. Thus, the CD4-dependent
component of an AE-COPD should depend heavily on
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Fig. 3 Representative graphs from individual subjects tracking percentages of CD4+ and CD8+ T cells during stable and exacerbation
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resident DC. Such activation is likely to be intact, because
during clinical stability expression of co-stimulatory sur-
face receptors by all three lung DC populations increases
in correlation with spirometrically-defined COPD pro-
gression [29, 30]. Moreover, lung DC from COPD can
polarize peripheral blood CD4+ T cells in vitro [31], sug-
gesting a similar role in the lungs.
By contrast, relative to lung CD8+ T cells from smokers
with preserved spirometry, lung resident CD8+ T cells
from COPD subjects have greater capacity to secrete pro-
inflammatory cytokines such as IFN-γ and TNF-α [11, 12].Because such secretion can be triggered by IL-18 without
the need for interaction with lung DC [11], lung resident
CD8+ T may not only respond appropriately to cognate
antigens (e.g., virally-infected lung epithelium), but might
also indiscriminately sustain inflammation through by-
stander activation. Hence, the lung resident CD8+ T cell
population, which increases in extent with worsening
FEV1 [13, 32, 33], appears quite capable of stimulating
lung damage by activating macrophages and by recruiting
other inflammatory cell types. However, the peripheral
blood of COPD patients also contains an increased propor-
tion of IFN-γ + and TNF-α +CD8+ T cells, relative to
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samples). Cells were stained and analyzed by flow cytometry. After
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red circles. The Wilcoxon matched-pairs signed rank test was used
to determine significant differences between visits
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the contribution of CD8+ T cells to inflammation in AE-
COPD also depends in part on cells acutely recruited from
the blood will be an important future goal.
The large body of experimental data on lymphocyte
trafficking [35] implies that the decreases we found in
blood CD4+ and CD8+ T cells during AE-COPD reflect
recruitment both of naïve and memory lymphocytes into
regional lymph nodes and organized lymphoid tissues
(which develop within lung parenchyma in advancedCOPD [33, 36]) and of effector-memory cells to the
lungs. The finding that blood T cell expression of activa-
tion markers showed no net change might reflect these
competing patterns of migration. It contrasts with evi-
dence of T cell activation on presentation during severe
asthma attacks [37]; the same study found that blood
CD4+ T cells of five subjects hospitalized for AE-COPD
showed increased expression of HLA-DR, which we did
not measure, but not of CD25, in agreement with our
data [37]. The disparity with the acute asthmatics might
relate to the lesser degree of acute stress in our subjects,
despite the severity of their underlying lung function in
the stable state, or may be due to differences between
the two diseases.
Our results in peripheral blood complement two stud-
ies showing increased percentages of total lymphocytes
(defined by cytospin differential counts) in sputum in
this setting [14, 15]. Collectively, these two studies and
ours imply that T cell recruitment to the lungs is a com-
ponent of AE-COPD, without proving causality in
pathogenesis. By contrast, no change in percentages of
lymphocytes in sputum or in density of CD4+ or CD8+
T cells in endobronchial biopsies was seen in an earlier
study, which did, however, find a significant increase
during exacerbation in airway wall numbers of CD3+ T
cells [16]. Another study of sputum during AE-COPD
found decreased CD4:CD8 ratios (assessed by immuno-
fluorescent staining of cytospins), relative to paired sam-
ples in the stable state, but no change in percentages of
lymphocytes (assessed morphologically) among total
sputum leukocytes [17]. Thus, controversy remains
about T cell recruitment to the lungs during AE-COPD.
We cannot address this controversy with our own spu-
tum data. At the time of this study, we were not yet
using flow cytometry to analyze sputum leukocyte sub-
sets, as we are now doing successfully in stable COPD
[20]. Our preliminary results suggest that to quantify
lymphocytes in respiratory secretions accurately, flow cy-
tometry will be superior to analysis of cytospins. This
question is being examined prospectively in the Subpop-
ulations and Intermediate Outcome Measures in COPD
study (SPIROMICS) [38]. Supporting this possibility,
paired comparisons of differential counts in bronchoal-
veolar lavage samples from humans and mice showed
that cytospins result in preferential loss of lymphocytes,
relative to more gentle sample preparation [39, 40]. Be-
cause flow cytometry also extends the identification of
lymphocyte subsets and their activation states in sputum
or other samples well beyond the capability of Giemsa-
stained cytospins, we believe that it has considerable
promise to investigate multiple airways diseases.
Our demonstration that serum GDF-15 levels rose in
uncomplicated AE-COPD treated successfully in outpa-
tients is significant, as this molecule has emerged as a
Table 2 Effect of COPD exacerbation on biomarkers in human sputum and serum
Sputum Serum
Biomarker Stable
(pg/mL)
Exacerbation
(pg/mL)
P-value Stable
(pg/mL)
Exacerbation
(pg/mL)
P-value
CCL2 462.1 ± 595.5 631.5 ± 960.4 0.52 373.6 ± 186.8 372.7 ± 227.0 1.0
CCL3 41.9 ± 27.5 58.0 ± 42.6 0.35 80.6 ± 35.8 86.7 ± 39.6 0.41
CCL4 110.8 ± 89.7 138.6 ± 116.4 0.64 128.9 ± 52.2 134.2 ± 57.3 0.64
CCL5 16.6 ± 4.0 16.9 ± 2.9 0.50 8,636 ± 2,200 8,500 ± 2,561 0.83
CCL7 16.3 ± 2.9 20.3 ± 11.5 0.44 61.1 ± 38.9 73.6 ± 56.9 0.40
CCL8 Not detected Not detected 15.5 ± 3.8 16.5 ± 7.6 0.89
CCL11 Not detected Not detected 79.7 ± 41.1 67.8 ± 56.7 0.06
CRP 8355 ± 12659 43812 ± 58313 0.004 0.58 ± 0.40 mg/L 6.37 ± 7.50 mg/L 0.0005
CXCL9 748.4 ± 863.8 641.5 ± 765.7 0.97 75.2 ± 32.8 84.9 ± 32.7 0.22
CXCL10 150.1 ± 101.2 568.4 ± 799.5 0.20 40.7 ± 8.9 67.8 ± 76.2 0.30
ENA-78 1544 ± 2243 573.5 ± 814.7 0.43 366.4 ± 278.8 435.6 ± 340.5 0.73
E-Selectin Not detected Not detected 4.5x104 ± 1.9x10 4.9x104 ± 1.7x104 0.72
GDF-15 ND ND 1,806 ± 1,558 2,295 ± 1,527 0.03
GRO-α 65.1 ± 72.5 52.7 ± 47.0 0.76 34.8 ± 31.1 43.7 ± 42.7 0.23
sICAM-1 1,370 ± 1,256 1,135 ± 1,118 0.81 2.6x105 ± 1.1x105 3.5x105 ± 1.0x105 0.004
IFN-α Not detected Not detected Not detected Not detected
IFN-β Not detected Not detected 802.9 ± 1096 1015.7 ± 1376 0.13
IFN-γ Not detected Not detected Not detected Not detected
IL-1β 20.3 ± 29.7 309.2 ± 567.2 0.15 Not detected Not detected
IL-1R1 ND ND Not detected Not detected
IL-1R2 ND ND Not detected Not detected
IL-1ra 34.9 ± 70 36.2 ± 54.7 0.43 Not detected Not detected
IL-6 117.1 ± 108.2 225.9 ± 193.5 0.16 11.9 ± 16.0 43.7 ± 103.6 0.21
sIL-6R Not detected Not detected 3.8x104 ± 1.3x104 4.0x104 ± 2.2x104 0.90
IL-8 3.7x106 ± 2.6x106 5.5x106 ± 4.3x106 0.16 33.7 ± 27.3 56.6 ± 40.0 0.16
IL-10 6.6 ± 4.7 27.6 ± 79.3 0.85 156.1 ± 299 260.0 ± 392 0.04
IL-15 Not detected Not detected 0.7 ± 0.1 5.2 ± 5.0 0.004
IL-17 Not detected Not detected Not detected Not detected
IL-18 40.7 ± 57.6 57.6 ± 100.3 0.99 20.9 ± 9.7 27.2 ± 13.3 0.18
IL-23 p19 Not detected Not detected Not detected Not detected
MMP-9 ND ND 8.1x105 ± 4.8x105 10.8x105 ± 5.9x105 0.37
MMP-12 9,758 ± 21,460 10,129 ± 19,529 0.85 ND ND
MPO 2.0x105 ± 1.2x105 2.5x105 ± 0.6x105 0.46 6.05x105 ± 4.4x105 5.6x105 ± 4.3x105 0.70
TIMP-1 381.4 ± 66.3 280.7 ± 72.9 0.016 8,973 ± 2,847 9,769 ± 2,185 0.42
TIMP-2 60.5 ± 26.1 116.9 ± 63.0 0.031 8,508 ± 13,251 8,958 ± 7,733 0.66
TIMP-3 Not detected Not detected 1,488 ± 979 1,313 ± 794 0.83
TIMP-4 Not detected Not detected 155.2 ± 69.3 125.1 ± 51.8 0.42
TNF-α ND ND 10.7 ± 5.8 16.9 ± 23.1 0.31
sTNFR1 14,681 ± 29,002 8,669 ± 15,039 0.96 1,829 ± 979 2,011 ± 570 0.27
sTNFR2 4,692 ± 6,700 9,140 ± 15,732 0.38 9,881 ± 5,189 10,488 ± 4,189 0.45
sVCAM-1 ND ND 1.4x106 ± 0.4x106 1.8x106 ± 0.3x106 0.014
VEGF Not detected Not detected Not detected Not detected
Data are shown as mean ± SD in pg/mL unless otherwise indicated; ND: not done
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Fig. 5 Soluble adhesion molecules and inflammatory mediators increased while CCL11 decreased in the serum during AE-COPD. Serum was
collected during stable visits and during AE-COPD, prior to medication (n = 18 paired samples). Samples were stored at −80 °C prior to analysis by
Luminex® assay, except as noted. (a) sICAM-1, (b) sVCAM-1, (c) IL-10, (d) IL-15, (e) GDF-15 (by ELISA), (f) CCL11 are shown. Open circles represent individual
subjects; mean ± SEM of the grouped data are shown by the single red circles. Note differences in units of measurement. The dotted line represents the
minimal detectable concentration. The Wilcoxon matched-pairs signed rank test was used to determine significant differences between visits
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volving pulmonary vasculature. GDF-15 is a divergent
TGF-beta superfamily member, first cloned from acti-
vated macrophages [41] and named Macrophage inhibi-
tory cytokine-1 (MIC-1). However, the same gene was
cloned by other strategies, leading to many alternative
names [42–45]. GDF-15 plays key regulatory roles in
processes as diverse as cell cycle progression, differenti-
ation, maintenance of pregnancy, apoptosis and tumor
progression [46, 47]. Serum levels of GDF-15 levels rise
modestly in acute coronary syndrome and congestive
heart failure, in both conditions accurately predicting
one-year mortality [48–50], but are very elevated in
acute pulmonary embolus [51] and pulmonary hyperten-
sion [52–54]. Elevated GDF-15 levels also predictedlong-term mortality in a population-based Swedish male
cohort (adjusted odd-ratio of death of 3.38, 95 % CI
1.38–8.26), independently of baseline IL-6 or CRP levels
[55]. Hence, this molecule merits additional study as a
COPD biomarker.
The elevation we demonstrated in serum IL-15 is sig-
nificant due to its multiple actions that could potentiate
lung inflammation during AE-COPD (reviewed in [56]).
These include antigen-independent activation of CD8+
T cells and enhanced effector function of CD8+ T cells,
NK cell and NK T cells. IL-15 also attracts and activates
neutrophils, while promoting their retention and delay-
ing apoptosis. This last action is shared with multiple
types of leukocytes and respiratory epithelial cells, and
might explain the previous observations that the fraction
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Fig. 6 CRP and TIMP-2 increased in sputum during AE-COPD,
whereas TIMP-1 decreased. Sputum was collected during stable
visits and during AE-COPD, prior to medication. After processing,
sputum supernatants were stored at −80 °C prior to analysis by
Luminex. (a) CRP, (b) TIMP-1, (c) TIMP-2 are shown (n = 10 paired
samples for CRP and n = 7 paired samples for TIMP-1 and TIMP-2).
Open circles represent individual subjects; mean ± SEM of the
grouped data are shown by the single red circles. The dotted line
represents the minimal detectable concentration. The Wilcoxon
matched-pairs signed rank test was used to determine significant
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AE-COPD [57, 58], although that finding might also re-
flect altered clearance. The lack of a parallel change in
IL-15 expression in sputum might indicate that its
source is not within the lungs, that its elaboration during
AE-COPD is directed away from the airway lumen, or
potentially that some factors during inflammation inhib-
ited its immunodetection. Dissociation of biomarker
concentrations between the peripheral blood and spu-
tum compartments, reflected in our measurements of
other biomarkers, is not unprecedented. A study analyz-
ing the expression during the stable state of 100 bio-
markers (including IL-15) in bronchoalveolar lavage,
bronchial biopsies, serum and induced sputum from
healthy smokers (n = 23) and COPD subjects (n = 24)
observed no correlations between lung and serum
biomarkers [59]. Additional investigation in larger co-
horts is needed to determine the most suitable bio-
markers to define the pathologic inflammatory processes
occurring within the airways during AE-COPD, which
may vary with the cause of specific episodes.
Multiple other circulating biomarkers of inflammation
are upregulated during AE-COPD (reviewed in [60]). Al-
though our finding of increased sVCAM is novel to our
knowledge, the elevations detected in CRP, IL-10 and
sICAM agree with some [22, 61, 62] but not all studies
[63]. We also observed an increase in mean serum levels
of both IL-6 and IL-8 during AE-COPD, as has been
seen by some [22, 62, 64], but not all studies [9]; how-
ever, neither attained statistical difference from stable
visits, likely due to our sample size. We did not see in-
creased MPO, TNF-α, or TNF receptors I and II during
AE-COPD, which others have reported.
Induced or spontaneously produced sputum has also
been analyzed extensively during AE-COPD, with eleva-
tions previously shown for IL-1β, IL-6, TNF-α, TNF recep-
tors I and II, CCL5, CCL4 [9], LTB4 [65] and MMP-9 [14].
We found marked but non-statistically significant eleva-
tions in sputum IL-1β concentrations and a non-significant
trend towards higher CXCL10 in serum, which a previous
analysis determined to be the two biomarkers that individu-
ally best discriminated bacterial AE-COPD from viral AE-
COPD, respectively [9]. The broad range of these measures
in our study could be taken to imply heterogeneous eti-
ologies; because we did not perform microbiological
analysis in this study, we cannot address that possibil-
ity. The current finding of reduced sputum TIMP-1
during AE-COPD, the only sputum analyte to decrease,
agrees with a previous study [14]. By contrast, we noted
increased TIMP-2, another inhibitor of MMPs. It is uncer-
tain why the two TIMPs differed, especially as they are
produced by multiple parenchymal lung cell types, in-
cluding bronchial epithelial cells, type II alveolar pneumo-
cytes and smooth muscle cells, plus by neutrophils and
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during AE-COPD are unknown. Although neither has
been directly implicated in lymphocyte recruitment to the
lungs, TIMP-1 does appear to regulate CD4+ T cell migra-
tion into brain parenchyma in a murine model of viral
encephalitis, independently of MMPs [67]. Furthermore,
new data is constantly emerging on the ability of TIMPs
to affect many other cellular functions, such as growth,
migration, and apoptosis [68]. We did not see increases in
any sputum biomarkers known to drive lymphocyte re-
cruitment, which may be due to a lack of power, but might
also argue that lymphocytes are not recruited to the lungs
during AE-COPD. However, two inter-related alternatives
should be considered: first, that chemokines responsible
for lymphocyte recruitment into lung parenchyma might
not be elevated in sputum due to preferential abluminal
secretion and binding to matrix; second, that lymphocytes
are recruited into lung parenchyma and especially intra-
epithelial sites during AE-COPD, but do not transmigrate
into airways and so cannot be detected in sputum. The
latter possibility merits testing.
Strengths of the current study include the rigorous
definition of AE-COPD as an event requiring a clinical
decision to treat with steroids, antibiotics or both by a
physician blinded to the biomarker data. The chief limi-
tation is the small number of subjects having paired
samples from stable and exacerbation visits. Based on
the highly productive experience of the East London co-
hort, we had originally planned a 100 subject cohort.
However, shortly after initiation of this study, both our
sites joined the NHLBI-sponsored trial of macrolide
therapy to prevent AE-COPD [69], which had similar
entry criteria. Many potential subjects preferred to en-
roll in that interventional trial, and we had limited suc-
cess in crossing over subjects on completion of their
year of study drug. Additionally, 13 of our subjects had
at least one self-reported AE-COPD for which they
sought medical attention locally rather than coming for
a study visit.
Conclusions
During event-defined AE-COPD, relative to paired sam-
ples collected during clinical stability, neutrophils in-
creased while CD4+ and CD8+ T cells (but not B cells,
NK cells or DC) decreased in peripheral blood, both
relatively and absolutely and in significant correlation
with serum CRP levels. There were also significant in-
creases in serum concentrations of GDF-15, a biomarker
of pulmonary vascular stress with known strong inde-
pendent prognostic value for long-term survival, and of
sICAM-1, sVCAM-1, IL-10 and IL-15. These findings
support the growing evidence that dysregulated inflam-
mation contributes to the morbidity of AE-COPD and
their sustained adverse effect on survival.During review of this article, GDF-15 was reported to be
elevated in 29 subjects hospitalized for AE-COPD, relative
to a separate group of subjects with stable COPD and to
healthy control subjects [70].
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